EATG » HIV treatment

HIV treatment

Doubt cast on link between tenofovir disoproxil and bone fractures

Study raises questions about the value of switching to more expensive tenofovir alafenamide Treatment with tenofovir disoproxil fumarate (TDF) does not increase the risk of fractures, according to French research…

CATIE: December 2018 issue of TreatmentUpdate now online

TreatmentUpdate is CATIE’s flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 229: Anti-HIV agents, December 2018 issue is available here.  

CD4 count recovery: French study reaffirms why it is important to test and treat HIV early

Seven-in-ten people with HIV taking combined antiretroviral therapy for the first time recover their CD4 cell count to above 500 cells/mm3, French researchers report in AIDS. Having a higher CD4…

Pharmaceutical corporations failing children with HIV

MSF criticises pharma for dragging feet on developing HIV drugs for children Geneva, 29 November 2018—Ahead of a Vatican City meeting on scaling up HIV diagnosis and treatment for children,…

EHVA: European HIV advocates discuss about new clinical study aiming to evaluate experimental strategies for the control of HIV infection

On Thursday, 15th of November, the European AIDS Treatment Group hosted a meeting with members of HIV organisations from six European countries to discuss the launch of the study EHVA…

PEPFAR, launched as an emergency response to AIDS, has built a bridge to the future

Just 15 years ago, in a historic act of global humanitarian leadership, President George W. Bush proposed in his 2003 State of the Union address the creation of the President’s Emergency Plan…

DELSTRIGO and PIFELTRO approved in Europe

European Commission approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO™ (doravirine), an NNRTI, both for the treatment…

All people with HIV-2 should receive HIV treatment – without it, most will progress to AIDS and death

Most people with HIV-2 infection will progress to AIDS and death unless they receive antiretroviral therapy (ART), according to the results of a study conducted in Guinea-Bissau and published in…

HIV and TB treatment at risk as countries gradually lose Global Fund support

-- Low- and middle-income countries receive donor support for HIV and TB drugs from the Global Fund, but are gradually losing this support -- Global Fund policies on countries that…

HIV i-Base, HTB: HIVR4P and Glasgow conferences: first reports

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. This issue of HTB includes the first reports from the recent HIV Treatment for Prevention (HIVR4P) and Glasgow…

1 2 3 68